Trial reportFrontiers in endocrinology2026
KunTai capsules combined with Femoston in premature ovarian insufficiency: a randomized controlled trial of the effects on bone mineral density.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the clinical efficacy of KunTai capsules combined with Femoston on bone mineral density (BMD) in women with premature ovarian insufficiency (POI). Methods: This prospective, randomized, controlled clinical trial was conducted at the First and Second Hospitals of Hebei Medical University from September 2018 to July 2022. Participants were randomly assigned in a 1:1 ratio to the control (Femoston alone) or the observation group (Femoston + KunTai capsules). Treatment duration was 12 months. The primary endpoint was the change in lumbar spine BMD at 12 months. Secondary endpoints included bone turnover markers (P1NP, β-CTX), hormone levels (E Results: A total of 104 women were randomized, and 73 completed the 12-month follow-up. After 12 months of treatment, the observation group demonstrated significant increases in total lumbar spine and L1-L4 BMD compared with baseline ( Conclusion: The combination of KunTai capsules and Femoston was associated with a greater increase in lumbar spine BMD at 12 months compared with Femoston monotherapy in women with POI. Improvements in menopausal symptoms were also observed; however, no significant between-group differences were found in bone turnover markers or hormone levels. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=26556, identifier (ChiCTR1800017774).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.